Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,491 across all filing types
Latest filing 2020-02-27 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, 3SBio Inc., detailing changes in issued share capital and share buybacks. It includes specific data on share repurchases, dates, prices, and confirmations of compliance with listing rules. The content focuses on share capital changes and repurchase activities, which aligns with announcements regarding share issues or capital changes. The document is not a full financial report, earnings release, or management discussion, but a regulatory disclosure about share capital changes and buybacks. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a formal disclosure report on capital changes.
2020-02-27 English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPROVAL FOR ANTI-IL-5 MONOCLONAL ANTIBODY BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the approval of a clinical trial application for an anti-IL-5 monoclonal antibody by the National Medical Products Administration. It provides detailed information about the product, the disease it targets, and a statement from the CEO. There are no financial statements, regulatory certifications, voting results, or management changes. The document is an announcement of a business development event rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2020-02-25 English
INSIDE INFORMATION ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to the Listing Rules of the Hong Kong Stock Exchange, specifically under rule 13.09 concerning Inside Information. It provides a preliminary assessment of the company's expected share of profit from joint ventures for the fiscal year ending 31 March 2020, referencing unaudited financial results of a joint venture and noting that the final consolidated results will be announced later. The document is relatively short (3226 characters) and does not contain detailed financial statements or comprehensive financial analysis. It serves as an update or notification to shareholders and investors about expected financial performance rather than a full financial report. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-02-20 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions within the board and its committees. It includes details about executive, non-executive, and independent non-executive directors, as well as their committee memberships. There is no financial data, no mention of a report or meeting results, and no indication of a report publication or regulatory filing. The content is focused on board composition and governance structure, which fits the category of Board/Management Information (MANG). The document length is short and purely informational about board members, not a report or announcement of voting results or remuneration details.
2020-02-10 English
(1) CHANGE OF NON-EXECUTIVE DIRECTOR AND (2) CHANGE OF COMPOSITION OF REMUNERATION COMMITTEE
Board/Management Information Classification · 100% confidence The document is an announcement from the Board of 3SBio Inc. regarding changes in the company's non-executive director and the composition of the Remuneration Committee. It details the resignation of Mr. Liu Dong and the appointment of Mr. Tang Ke as a non-executive director and member of the Remuneration Committee. The content focuses on board and committee membership changes, biographical details of the new appointee, and related governance matters. There is no financial data, earnings information, or report publication mentioned. The document is not a full report but an official announcement of management/board changes. Therefore, it fits the category of Board/Management Information (MANG). The document length (6631 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2020-02-10 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions for the month ended 31/01/2020. It is addressed to the Hong Kong Exchanges and Clearing Limited, indicating it is a regulatory filing related to share capital movements. The content is a detailed report of share capital changes rather than an announcement or summary. It does not contain financial performance data, earnings, or management commentary. It is not a full annual or interim report, nor is it a call transcript or AGM material. The document is a regulatory compliance filing reporting share capital movements, which fits best under the category of Share Issue/Capital Change (SHA).
2020-02-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.